SSTR2 and acromegaly: For example the single-receptor-targeted somatostatin analogs (SAs), octreotide and lanreotide, which act predominantly via the somatostatin receptor type 2 (SSTR2), have been reported to be effective in decreasing pituitary NET GH secretion and growth in up to 70 and 75% of patients with acromegaly, respectively (15, –, 19).